AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 3336176 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical tretinoin
Number of subjects: 30
Study 3336176 — intervention group
Group type: COMPARATOR
Intervention: Vehicle cream
Number of subjects: 30
Study 28303421 — intervention group
Group type: EXPERIMENTAL
Intervention: Group Coping Power
Number of subjects: 197
Study 28303421 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual Coping Power
Number of subjects: 197
Study 28303421 — intervention group
Group type: EXPERIMENTAL
Intervention: A/A genotype
Number of subjects: 197
Study 28167746 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient rehabilitation programme
Number of subjects: 0
Study 28167746 — intervention group
Group type: COMPARATOR
Intervention: Home exercise programme (Control)
Number of subjects: 0
Study 26665460 — intervention group
Group type: EXPERIMENTAL
Intervention: Parecoxib 40 mg by muscle injection 30 min before the operation followed by saline every 24 h for 48 h (Group A)
Number of subjects: 120
Study 26665460 — intervention group
Group type: EXPERIMENTAL
Intervention: Parecoxib 40 mg by muscle injection 30 min before the operation followed by 40 mg every 24 h for 48 h (Group B)
Number of subjects: 120
Study 26665460 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline at the same time points (Control Group C)
Number of subjects: 120
Study 26665460 — intervention group
Group type: EXPERIMENTAL
Intervention: Both Group A and Group B
Number of subjects: 120
Study 23905652 — intervention group
Group type: EXPERIMENTAL
Intervention: Black pepper (2.0 g)
Number of subjects: 40
Study 23905652 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosemary (1.7 g)
Number of subjects: 40
Study 23905652 — intervention group
Group type: COMPARATOR
Intervention: Placebo (3.1 g rice flour)
Number of subjects: 40
Study 21692235 — intervention group
Group type: EXPERIMENTAL
Intervention: Lornoxicam (LNX) 8 mg
Number of subjects: 114
Study 21692235 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac potassium (DP) 50 mg
Number of subjects: 114
Study 21692235 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLAC) cellulose powder
Number of subjects: 114
Study 19446402 — intervention group
Group type: EXPERIMENTAL
Intervention: ACTION smoking cessation program
Number of subjects: 260
Study 19446402 — intervention group
Group type: COMPARATOR
Intervention: Comparison participants (control group)
Number of subjects: 260
Study 16375852 — intervention group
Group type: EXPERIMENTAL
Intervention: Reinstatement group (one or four unpredicted UCS-only trials)
Number of subjects: 0
Study 16375852 — intervention group
Group type: COMPARATOR
Intervention: Control group (no additional UCS presentations)
Number of subjects: 0
Study 14727000 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 60 mg daily
Number of subjects: 175
Study 14727000 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine 30 mg daily
Number of subjects: 175
Study 11395188 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (25 mg/day for 3 days)
Number of subjects: 20
Study 11395188 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 11395188 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 20
Study 9223109 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytocidal IgM anti-Fas mAb
Number of subjects: 0
Study 9223109 — intervention group
Group type: COMPARATOR
Intervention: Antagonistic anti-FasR mAb
Number of subjects: 0
Study 8425445 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactose challenge (2 g/kg) in lactose-intolerant children
Number of subjects: 110
Study 8425445 — intervention group
Group type: COMPARATOR
Intervention: Lactose challenge (2 g/kg) in normal children
Number of subjects: 110
Study 2906174 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine 10 mg four times daily plus placebo
Number of subjects: 12
Study 2906174 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine 10 mg four times daily plus famotidine 40 mg once daily
Number of subjects: 12
Study 2906174 — intervention group
Group type: EXPERIMENTAL
Intervention: Famotidine 40 mg once daily
Number of subjects: 12
Study 29289727 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride dentifrice (1150 ppm) + Fluoride mouthrinse (220 ppm)
Number of subjects: 53
Study 29289727 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride dentifrice (1150 ppm) + No rinse
Number of subjects: 53
Study 29289727 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo dentifrice + Fluoride mouthrinse (220 ppm)
Number of subjects: 53
Study 27020873 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthodontic bands on first permanent molars
Number of subjects: 25
Study 27020873 — intervention group
Group type: COMPARATOR
Intervention: Directly bonded tubes on the labial surface of first permanent molars
Number of subjects: 25
Study 25917680 — intervention group
Group type: EXPERIMENTAL
Intervention: Live-attenuated influenza vaccine (LAIV)
Number of subjects: 300
Study 25917680 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study 23758929 — intervention group
Group type: EXPERIMENTAL
Intervention: INVOS monitoring
Number of subjects: 150
Study 23758929 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 150
Study 23758929 — intervention group
Group type: EXPERIMENTAL
Intervention: INVOS monitoring (intention to treat analysis)
Number of subjects: 150
Study 23758929 — intervention group
Group type: COMPARATOR
Intervention: Control group (intention to treat analysis)
Number of subjects: 150
Study 21963834 — intervention group
Group type: EXPERIMENTAL
Intervention: Neck suction (NS; carotid hypertension) at -60 Torr
Number of subjects: 40
Study 21963834 — intervention group
Group type: COMPARATOR
Intervention: Neck pressure (NP; carotid hypotension) at +40 Torr
Number of subjects: 40
Study 21963834 — intervention group
Group type: COMPARATOR
Intervention: Neck pressure (NP; carotid hypotension)
Number of subjects: 40
Study 19808280 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised aerobic exercise training at 70% of peak o(2) 3 times a week for 8 weeks (group E, n=44)
Number of subjects: 130
Study 19808280 — intervention group
Group type: EXPERIMENTAL
Intervention: Waltz dancing protocol (group D, n=44)
Number of subjects: 130
Study 19808280 — intervention group
Group type: COMPARATOR
Intervention: Control group (group C, n=42)
Number of subjects: 130
Study 21937568 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone/naloxone prolonged-release tablets (OXN PR)
Number of subjects: 185
Study 21937568 — intervention group
Group type: COMPARATOR
Intervention: Oxycodone prolonged-release tablets (OxyPR)
Number of subjects: 185
Study 16054413 — intervention group
Group type: EXPERIMENTAL
Intervention: GH treatment (subcutaneous injections of GH 0.03 IU/kg/daily) for 5 days
Number of subjects: 6
Study 16054413 — intervention group
Group type: EXPERIMENTAL
Intervention: IGF-I treatment (continuous subcutaneous infusion of 5 microg/kg/h recombinant IGF-I) for 5 days
Number of subjects: 6
Study 12056182 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh young coconut water (CW)
Number of subjects: 8
Study 12056182 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate-electrolyte beverage (CEB)
Number of subjects: 8
Study 12056182 — intervention group
Group type: COMPARATOR
Intervention: Plain water (PW)
Number of subjects: 8
Study 9522112 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium channel blocker therapy
Number of subjects: 0
Study 9522112 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study 7877347 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbimazole (decreasing doses)
Number of subjects: 76
Study 7877347 — intervention group
Group type: COMPARATOR
Intervention: Carbimazole (high doses) plus Levothyroxine
Number of subjects: 76
Study 1688617 — intervention group
Group type: EXPERIMENTAL
Intervention: MACOP-B chemotherapy regimen (methotrexate, doxorubicin, cyclophosphamide, vincristine, prednisone, and bleomycin)
Number of subjects: 70
Study 1688617 — intervention group
Group type: EXPERIMENTAL
Intervention: MACOP-B chemotherapy regimen
Number of subjects: 70
Study 82144 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin prophylaxis
Number of subjects: 12
Study 12117628 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 680
Study 12117628 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 680
Study 12117628 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 680
Study 31297962 — intervention group
Group type: EXPERIMENTAL
Intervention: Immune checkpoint inhibitors (ICIs)
Number of subjects: 6278
Study 31297962 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus chemotherapy
Number of subjects: 6278
Study 31297962 — intervention group
Group type: COMPARATOR
Intervention: ICIs plus chemotherapy
Number of subjects: 6278
Study 30165522 — intervention group
Group type: EXPERIMENTAL
Intervention: Training in communication skills
Number of subjects: 5
Study 30165522 — intervention group
Group type: EXPERIMENTAL
Intervention: Training in CRP testing
Number of subjects: 5
Study 30165522 — intervention group
Group type: EXPERIMENTAL
Intervention: Training in both CRP testing and communication skills
Number of subjects: 5
Study 30165522 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 5
Study 26915737 — intervention group
Group type: EXPERIMENTAL
Intervention: Explicit training condition
Number of subjects: 80
Study 26915737 — intervention group
Group type: COMPARATOR
Intervention: Implicit training condition
Number of subjects: 80
Study 24626141 — intervention group
Group type: EXPERIMENTAL
Intervention: Block Start (BS)
Number of subjects: 16
Study 24626141 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhythm Step (RS)
Number of subjects: 16
Study 24626141 — intervention group
Group type: COMPARATOR
Intervention: Forward Step (FS)
Number of subjects: 16
Study 22268699 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractionated CO2 laser therapy
Number of subjects: 2
Study 22268699 — intervention group
Group type: COMPARATOR
Intervention: Dermabrasion
Number of subjects: 2
Study 20214154 — intervention group
Group type: EXPERIMENTAL
Intervention: Zygote intrafallopian transfer (ZIFT)
Number of subjects: 220
Study 20214154 — intervention group
Group type: COMPARATOR
Intervention: Uterine embryo transfer (UET)
Number of subjects: 220
Study 17570634 — intervention group
Group type: EXPERIMENTAL
Intervention: Echocardiographic guidance with MitraClip
Number of subjects: 47
Study 15726120 — intervention group
Group type: EXPERIMENTAL
Intervention: EoP (Cisplatin plus oral etoposide); etoposide 50 mg p.o. twice a day for 7 days, cisplatin 70 mg/m² i.v. on day 1, repeated every 3 weeks.
Number of subjects: 201
Study 15726120 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel; 175 mg/m² i.v. on day 1, repeated every 3 weeks.
Number of subjects: 201
Study 12799102 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy (HRT) with conjugated estrogen and medroxyprogesterone for 3 months
Number of subjects: 28
Study 12799102 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy (HRT)
Number of subjects: 28
Study 12799102 — intervention group
Group type: COMPARATOR
Intervention: Non-HRT control group
Number of subjects: 28
Study 10372237 — intervention group
Group type: EXPERIMENTAL
Intervention: High carbohydrate diet (10% fat, 4% saturated)
Number of subjects: 35
Study 10372237 — intervention group
Group type: EXPERIMENTAL
Intervention: High monounsaturated fat (MUFA) diet (32% fat, 7% saturated)
Number of subjects: 35
Study 10372237 — intervention group
Group type: COMPARATOR
Intervention: High saturated fat (SFA) diet (32% fat, 17% saturated)
Number of subjects: 35
Study 10372237 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy restriction (1,600 kcal/day for 12 weeks)
Number of subjects: 35
Study 8888304 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-body clips
Number of subjects: 0
Study 8888304 — intervention group
Group type: EXPERIMENTAL
Intervention: Upright biological-motion displays
Number of subjects: 0
Study 8888304 — intervention group
Group type: EXPERIMENTAL
Intervention: Inverted biological-motion displays
Number of subjects: 0
Study 1839161 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacidipine
Number of subjects: 0
Study 1839161 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Number of subjects: 0
Study 6848680 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenytoin
Number of subjects: 244
Study 6848680 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 244
Study 31345964 — intervention group
Group type: EXPERIMENTAL
Intervention: ASSIST 1.0 intervention programme (theory-based reablement programme including coaching of home care staff and digitally based smart products)
Number of subjects: 30
Study 31345964 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 30
Study 30128952 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Rehabilitation (CR)
Number of subjects: 53
Study 30128952 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurofeedback (NFB)
Number of subjects: 53
Study 30128952 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated)
Number of subjects: 53
Study 27890050 — intervention group
Group type: EXPERIMENTAL
Intervention: Interprofessional medication management
Number of subjects: 142
Study 27890050 — intervention group
Group type: COMPARATOR
Intervention: Control phase
Number of subjects: 142
Study 24667908 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary patterns from the DASH study
Number of subjects: 0
Study 24667908 — intervention group
Group type: EXPERIMENTAL
Intervention: Linear mixed model analysis
Number of subjects: 0
Study 22990034 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting fMRI scan
Number of subjects: 23
Study 22990034 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-breakfast fMRI scan
Number of subjects: 23
Study 20672451 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose nevirapine + zidovudine + lamivudine
Number of subjects: 198
Study 20672451 — intervention group
Group type: COMPARATOR
Intervention: Single-dose nevirapine
Number of subjects: 198
Study 17006363 — intervention group
Group type: EXPERIMENTAL
Intervention: All-polyethylene tibial component
Number of subjects: 290
Study 17006363 — intervention group
Group type: COMPARATOR
Intervention: Metal-backed tibial component
Number of subjects: 290
Study 16264111 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal shock waves (6000 impulses at 28 kV)
Number of subjects: 48
Study 16264111 — intervention group
Group type: COMPARATOR
Intervention: Core decompression and nonvascularized fibular grafting
Number of subjects: 48
Study 12028899 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon (IFN) 4.5 MU/daily for 24 weeks, followed by 4.5 MU/48 hours for a further 24 weeks (if ALT was normal)
Number of subjects: 40
Study 12028899 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 40
Study 10202389 — intervention group
Group type: EXPERIMENTAL
Intervention: Green tea
Number of subjects: 18
Study 10202389 — intervention group
Group type: EXPERIMENTAL
Intervention: Black tea
Number of subjects: 18
Study 10202389 — intervention group
Group type: COMPARATOR
Intervention: Black tea with milk
Number of subjects: 18
Study 10202389 — intervention group
Group type: COMPARATOR
Intervention: Water
Number of subjects: 18
Study 10202389 — intervention group
Group type: EXPERIMENTAL
Intervention: LDL oxidizability
Number of subjects: 18
Study 7849295 — intervention group
Group type: EXPERIMENTAL
Intervention: CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone)
Number of subjects: 376
Study 2351039 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructosamine measurements
Number of subjects: 0
Study 2351039 — intervention group
Group type: COMPARATOR
Intervention: HbA1 measurements
Number of subjects: 0
Study 2351039 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall correlation between HbA1 and glucose
Number of subjects: 0
Study 2351039 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between fructosamine and HbA1
Number of subjects: 0
Study 2351039 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between fructosamine and glucose
Number of subjects: 0
Study 2351039 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal fructosamine results
Number of subjects: 0
Study 6966882 — intervention group
Group type: EXPERIMENTAL
Intervention: terodiline 12.5 mg twice daily
Number of subjects: 12
Study 6966882 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study 30362650 — intervention group
Group type: EXPERIMENTAL
Intervention: CAD/CAM-processed implant crowns
Number of subjects: 20
Study 27900662 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyalobarrier®
Number of subjects: 30
Study 27900662 — intervention group
Group type: COMPARATOR
Intervention: No Hyalobarrier® (control)
Number of subjects: 30
Study 24531123 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 g dark chocolate
Number of subjects: 21
Study 24531123 — intervention group
Group type: COMPARATOR
Intervention: 50 g white chocolate (control)
Number of subjects: 21
Study 24531123 — intervention group
Group type: COMPARATOR
Intervention: dark chocolate and white chocolate
Number of subjects: 21
Study 24603643 — intervention group
Group type: EXPERIMENTAL
Intervention: NEPA (300 mg netupitant + 0.50 mg palonosetron)
Number of subjects: 1455
Study 22871128 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium citrate supplementation (600 mg·kg(‐1); CIT group)
Number of subjects: 16
Study 22871128 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLC group)
Number of subjects: 16
Study 19953772 — intervention group
Group type: EXPERIMENTAL
Intervention: SoloBond M two‐step etch‐and‐rinse adhesive
Number of subjects: 16
Study 19953772 — intervention group
Group type: COMPARATOR
Intervention: FuturaBond NR one‐step self‐etch adhesive
Number of subjects: 16
Study 18292704 — intervention group
Group type: EXPERIMENTAL
Intervention: Laboratory research and treatment trials for marijuana dependence; specific interventions not detailed.
Number of subjects: 0
Study 16801747 — intervention group
Group type: EXPERIMENTAL
Intervention: Local guidelines, de-escalation, rotation and association therapies
Number of subjects: 0
Study 12546525 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-FU 400 mg/m2 (group A)
Number of subjects: 312
Study 12546525 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-FU 500 mg/m2 (group B)
Number of subjects: 312
Study 12546525 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-FU 600 mg/m2 (group C)
Number of subjects: 312
Study 10643517 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium-para-aminobenzoate
Number of subjects: 0
Study 10643517 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen or interferon therapy
Number of subjects: 0
Study 10643517 — intervention group
Group type: EXPERIMENTAL
Intervention: Small incision graft
Number of subjects: 0
Study 10643517 — intervention group
Group type: EXPERIMENTAL
Intervention: Iontophoresis
Number of subjects: 0
Study 10643517 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporal shock wave therapy
Number of subjects: 0
Study 7674464 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin acetate (DDAVP) 20 micrograms
Number of subjects: 91
Study 7674464 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study 7674464 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin acetate (DDAVP)
Number of subjects: 91
Study 2291867 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (12.5, 25, and 50 mg)
Number of subjects: 14
Study 2291867 — intervention group
Group type: COMPARATOR
Intervention: Oxazepam (15 mg)
Number of subjects: 14
Study 2291867 — intervention group
Group type: COMPARATOR
Intervention: Atenolol (100 mg)
Number of subjects: 14
Study 6114712 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined H1 (hydroxyzine hydrochloride) and H2 (cimetidine) antihistamines
Number of subjects: 18
Study 6114712 — intervention group
Group type: COMPARATOR
Intervention: H1 antihistamines alone
Number of subjects: 18
Study 31199705 — intervention group
Group type: EXPERIMENTAL
Intervention: Huoxin formula (13.5 g granules dissolved in 150 mL warm water, twice a day)
Number of subjects: 58
Study 31199705 — intervention group
Group type: COMPARATOR
Intervention: Control group (only cardiovascular drugs)
Number of subjects: 58
Study 31199705 — intervention group
Group type: EXPERIMENTAL
Intervention: Huoxin formula
Number of subjects: 58
Study 31199705 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 58
Study 28575224 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol 1000 IU/d from 14 weeks of gestation until delivery
Number of subjects: 682
Study 28575224 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 682
Study 28029540 — intervention group
Group type: EXPERIMENTAL
Intervention: Booster dose of combined Haemophilus influenzae type b and MenC‐tetanus toxoid vaccine (Hib‐MenC‐TT)
Number of subjects: 269
Study 28029540 — intervention group
Group type: EXPERIMENTAL
Intervention: One MenC‐TT dose
Number of subjects: 269
Study 28029540 — intervention group
Group type: EXPERIMENTAL
Intervention: Two MenC‐CRM vaccine doses
Number of subjects: 269
Study 28029540 — intervention group
Group type: COMPARATOR
Intervention: Infant MenCC naïve group
Number of subjects: 269
Study 24929023 — intervention group
Group type: EXPERIMENTAL
Intervention: H2-saline infusion (1 ppm H2-dissolved saline)
Number of subjects: 24
Study 24929023 — intervention group
Group type: COMPARATOR
Intervention: Placebo-saline infusion
Number of subjects: 24
Study 22344504 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced eGFR laboratory prompt
Number of subjects: 5444
Study 22344504 — intervention group
Group type: COMPARATOR
Intervention: Standard eGFR laboratory prompt
Number of subjects: 5444
Study 22344504 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced eGFR laboratory prompt (subgroup with eGFR <30 ml/min per 1.73 m²)
Number of subjects: 5444
Study 22344504 — intervention group
Group type: COMPARATOR
Intervention: Standard eGFR laboratory prompt (subgroup with eGFR <30 ml/min per 1.73 m²)
Number of subjects: 5444
Study 22344504 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall CKD management (composite clinical outcome)
Number of subjects: 5444
Study 19546122 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone bulking agent injection
Number of subjects: 35
Study 19546122 — intervention group
Group type: COMPARATOR
Intervention: Control group (20 continent healthy volunteers)
Number of subjects: 35